- Home
- LU vs CPRX Comparison
LU vs CPRX Comparison
Compare LU & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- CPRX
- Stock Information
- Founded
- LU 2005
- CPRX 2002
- Country
- LU China
- CPRX United States
- Employees
- LU N/A
- CPRX N/A
- Industry
- LU Finance: Consumer Services
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- LU Finance
- CPRX Health Care
- Exchange
- LU Nasdaq
- CPRX Nasdaq
- Market Cap
- LU 2.5B
- CPRX 2.9B
- IPO Year
- LU 2020
- CPRX 2006
- Fundamental
- Price
- LU $2.73
- CPRX $21.62
- Analyst Decision
- LU Hold
- CPRX Strong Buy
- Analyst Count
- LU 2
- CPRX 6
- Target Price
- LU $2.98
- CPRX $32.83
- AVG Volume (30 Days)
- LU 2.2M
- CPRX 1.4M
- Earning Date
- LU 08-20-2025
- CPRX 08-06-2025
- Dividend Yield
- LU N/A
- CPRX N/A
- EPS Growth
- LU N/A
- CPRX 178.13
- EPS
- LU N/A
- CPRX 1.57
- Revenue
- LU $4,671,260,668.00
- CPRX $534,645,999.00
- Revenue This Year
- LU N/A
- CPRX $16.37
- Revenue Next Year
- LU N/A
- CPRX $8.80
- P/E Ratio
- LU N/A
- CPRX $13.78
- Revenue Growth
- LU N/A
- CPRX 29.97
- 52 Week Low
- LU $2.13
- CPRX $15.34
- 52 Week High
- LU $4.15
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- LU 44.01
- CPRX 40.61
- Support Level
- LU $2.72
- CPRX $20.62
- Resistance Level
- LU $2.84
- CPRX $21.62
- Average True Range (ATR)
- LU 0.07
- CPRX 0.63
- MACD
- LU -0.01
- CPRX 0.06
- Stochastic Oscillator
- LU 30.23
- CPRX 52.08
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).